· First long-acting canine anti-nerve growth factor monoclonal antibody therapy administered once every three months
· Approval marks major milestone in the company’s continued innovation for canine osteoarthritis pain
LEATHERHEAD, UK – May 28, 2026 – Zoetis UK Ltd. announced that the UK’s Veterinary Medicines Directorate (VMD) has approved Lenivia® (izenivetmab injection) for the alleviation of pain associated with osteoarthritis in dogs. Backed by a decade of science and research, Lenivia is a new antibody therapy that, in a field study, showed dogs receiving it experienced improved mobility and reduced pain after a single injection. Lenivia offers effective alleviation from pain associated with osteoarthritis for up to three months with a single injection, acting via its novel binding to nerve growth factor (NGF), a recognised mediator of pain and inflammation.
“Lenivia’s approval marks a meaningful milestone in our continued innovation for canine osteoarthritis pain,” said Julia von Gablenz, Regional President, Europe & Middle East of Zoetis. “Dogs with osteoarthritis can experience persistent pain that affects comfort, mobility, and quality of life. With Lenivia’s approval, we’re proud to bring UK(GB) veterinary professionals a new, long-acting option that can help alleviate osteoarthritis-associated pain and support sustained comfort with a single injection.”
Significance of Osteoarthritis Pain
Osteoarthritis is a common, chronic and progressive joint disease characterised by the inflammation and breakdown of joints, leading to pain and mobility issues. Although the disease cannot be cured, much can be done to alleviate the associated pain and help improve quality of life. Nearly 40 percent of dogs of any age or size may be affected by osteoarthritis pain1, 2, and chronic pain can negatively impact dogs’ movement, sleep, behavior and social relationships3.
Continued Innovation to Meet Medical Needs
Zoetis continues to advance care for animals around the globe with a robust pipeline fueled by lifecycle innovation, geographic expansion and new innovation. Lenivia builds on Zoetis’ established portfolio, backed by extensive scientific research in veterinary monoclonal antibodies.
By offering a long-acting injectable option, Lenivia is indicated to help alleviate pain associated with osteoarthritis as part of an individualised management plan developed by the veterinary professional. Lenivia should be used under the guidance of a veterinary professional and in accordance with the approved GB product information.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
About Lenivia
Lenivia is a monoclonal antibody therapy that binds to NGF to reduce NGF’s effects. Lenivia is indicated for the alleviation of pain associated with osteoarthritis in dogs. Lenivia is administered subcutaneously once every three months. For full clinical and safety information, including indications, contraindications, special warnings and adverse events please refer to the product SPC.
1Wright A, Amodie DM, Cernicchiaro N, et al. Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests. J Small Anim Pract. 2022;63(8):609-618.
2Enomoto M, de Castro N, Hash J, et al. Prevalence of radiographic appendicular osteoarthritis and associated clinical signs in young dogs. Sci Rep. 2024;14(1):2827.
3Lascelles BDX, Brown DC, Conzemius MG, Gill M, Oshinsky ML, Sharkey ML. Measurement of chronic pain in companion animals: discussions from the Pain in Animals Workshop (PAW) 2017. Vet J. 2019;250:71-78.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements which reflect the current views of Zoetis with respect to: our business plans or prospects; expectations regarding products, product approvals or licenses, products under development; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialise, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
MM-49405 | May 2026
# # #